# Cardiovalve TR System in TARGET study: 76.9% of patients with none/trace TR at 3 years

- Published: 2026-11-22 16:25 UTC
- Section: Life & Health › Medtech
- Tags: Cardiovalve TR System, TARGET study, tricuspid regurgitation, Venus Medtech, PCR London Valves 2026, high-risk patients, right heart remodeling, KCCQ, CE Mark
- URL: https://realtech.media/news/rt-78b6b536b764b0f358a75419_cardiovalve_tr_system/

**Single-arm TARGET trial of the Cardiovalve TR System in 157 high-risk patients with severe tricuspid regurgitation met its primary performance and safety endpoints, the company reports.**

![Cardiovalve TR System in TARGET study: 76.9% of patients with none/trace TR at 3 years](https://realtech.media/media/2026/11/2514bf88040769e5.jpg)
*prnewswire.com*

Venus Medtech (Hangzhou) Inc. (2500.HK) announced on Nov. 22, 2026, in London the results of the TARGET Study, a multicenter, prospective, single-arm, open-label trial of the safety and performance of the Cardiovalve TR System, according to prnewswire.com [1]. The data were presented at PCR London Valves 2026 by Prof. Georg Nickenig of the Heart Center, University Hospital Bonn, Germany, on behalf of the study investigators. The company states that both primary endpoints, performance and safety, were met [1].

The study enrolled 157 symptomatic patients (148 implanted) with at least severe tricuspid regurgitation (TR) who were at high risk for open-heart surgery. The mean age was 78 years, 71% were female, 99% had secondary TR and nearly 40% had torrential TR [1].

## Performance and right heart remodeling

At 30 days, the primary performance endpoint, successful implantation with ≤2+ TR, was met. According to the company, TR reduction was sustained up to 3 years, with 76.9% of patients having none/trace TR at the 3-year mark [1].

At 1 year, the mean increase in the 6-minute walk test was 42 meters, and the Kansas City Cardiomyopathy Questionnaire (KCCQ) score rose by 20 points. At 3 years, 80% of patients were in NYHA Class I or II, compared with 39.9% at baseline [1].

Mean reductions at 3 years were 25% in inferior vena cava (IVC) diameter, 22% in mid right ventricular end-diastolic diameter (RVEDD) and 11% in basal RVEDD, which the company describes as reverse right heart remodeling [1].

## Safety and regulatory status

The primary safety endpoint was a composite of major adverse events at 30 days per the TVARC definition, and it was met [1]. At 30 days, all-cause mortality was 5.7%, heart failure rehospitalization was 1.9%, and major access site and vascular injury requiring surgical intervention was 5.1% [1].

The Enhanced Delivery System was compared with the 1st Generation Delivery System. Major bleeding was 5.0% versus 21%, and major vascular complications were 3.0% versus 8.8% [1].

Cardiovalve is a subsidiary of Venus Medtech. The company says it continues the regulatory process toward CE Mark approval and expects potential EU commercialization in the second half of 2027 [1].

## Sources

1. [prnewswire.com](https://www.prnewswire.com/news-releases/target-study-demonstrates-sustained-performance-and-favorable-safety-profile-of-the-cardiovalve-tr-system-in-high-risk-patients-with-severe-tricuspid-regurgitation-302947606.html)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-78b6b536b764b0f358a75419_cardiovalve_tr_system/
